Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Anal Cancer
Interventions: fluorouracil, mitomycin C, Intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 169
States / cities: Tucson, Arizona • Auburn, California • Burbank, California + 128 more

Conditions: Candidiasis
Interventions: Caspofungin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Invasive Fungal Infections
Interventions: SUBA itraconazole, Conventional itraconazole; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Early NIPPV, Standard NIPPV; Device
Lead sponsor: Edward Kasaraskis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 12
States / cities: Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more

Conditions: Aphasia
Interventions: rTMS, tDCS, Sham rTMS, Sham tDCS; Device
Lead sponsor: Dr. Alexander Thiel; Individual
Eligibility: 50 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Atrial Fibrillation, Esophageal Carcinoma
Interventions: Amiodarone Hydrochloride, Saline; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Intraoperative Ureter Injury
Interventions: Nerindocianine for Injection; Drug
Lead sponsor: Li-Cor, Inc.; Industry
Eligibility: 19 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Ventilation, Capnography
Interventions: Linshom Respiratory Monitoring Device; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Bladder Cancer, High Grade, Non Muscle Invasive
Interventions: oncolytic adenovirus expressing GMCSF; Biological
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes, Diabetic Ketoacidosis
Interventions: this is not an intervention study, MRI; Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: PARKINSON DISEASE (Disorder)
Interventions: Vibrotactile stimulation; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Adipose Tissue Atrophy
Interventions: Venus Bliss; Device
Lead sponsor: Venus Concept; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Los Altos, California • Sacramento, California • Santa Monica, California + 2 more

Conditions: Invasive Fungal Infections
Interventions: APX001, APX001A; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostatectomy, Nephrectomy, Laparoscopy, Robotics
Interventions: Teleflex HemoLock clip, Aesculap U-clip; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bladder Cancer
Interventions: Targeted Interventions for Impairments Identified During Geriatric Assessment; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bladder Cancer, Diabetes Mellitus
Interventions: CR diet, Exercise; Other · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency, Mitral Incompetence, Ischemic Heart Disease
Interventions: Percutaneous mitral valve repair; Device
Lead sponsor: Myocor; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • Evanston, Illinois • Shawnee Mission, Kansas + 1 more

Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions: UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization; Device
Lead sponsor: St. Louis University; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma, Resectable Breast Carcinoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Heart Failure
Interventions: SimpleSENSE; Device
Lead sponsor: Nanowear Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions: Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO); Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Osteoarthritis
Interventions: Active Device (Torino II), Sham Device (Torino II); Device
Lead sponsor: Center for Joint Surgery and Sports Medicine, Maryland; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Hagerstown, Maryland

Conditions: Graft Rejection, Heart Diseases
Interventions: AlloMap molecular expression testing, Right ventricular endomyocardial biopsy; Device · Procedure
Lead sponsor: XDx; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 13
States / cities: Palo Alto, California • Stanford, California • Chicago, Illinois + 9 more

Search by objective public record fields.

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NOn-invasive Repeated THerapeutic STimulation for Aphasia Recovery

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

Evaluation of a Non-invasive Brain Compliance Measurement Device

Vibrotactile Stimulation for Parkinson's Disease

Clinical Evaluation of a 1060 nm Diode Laser, PEMF and Vacuum Assisted MP RF for Non-invasive Fat Reduction

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Nanowear Heart Failure Management Multi-sensor Algorithm

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain

IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection